|
|
|
MIRA
INFORM REPORT
|
Report No. : |
490181 |
|
Report Date : |
06.02.2018 |
IDENTIFICATION DETAILS
|
Name : |
HAN LIM PHARM CO., LTD. |
|
|
|
|
Registered Office : |
2-27,
Yeongmun-ro, Cheoin-gu, Yongin-si, Gyeonggi-do, Korea, 17040 |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Financials (as on) : |
31.12.2016 |
|
|
|
|
Date of Incorporation : |
14.03.1989 |
|
|
|
|
Com. Reg. No.: |
135-81-02638 |
|
|
|
|
Legal Form : |
Co., Ltd by Shares |
|
|
|
|
Line of Business : |
Manufacture of Finished Products, Pharmaceuticals, Bulk Drugs, Antiinflammatory, Analgesics, Antirheumatics, Antibacterials, Alimentary Drugs, Allergy & ENT Disease Related Agents |
|
|
|
|
No. of Employees : |
342 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A |
|
Credit Rating |
Explanation |
Rating Comments |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.06.2017) |
Current Rating (30.09.2017) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
SOUTH KOREA - ECONOMIC OVERVIEW
After emerging from the 1950-53 war with North Korea, South Korea emerged as one of the 20th century’s most remarkable economic success stories, becoming a developed, globally connected, high-technology society within decades. In the 1960s, GDP per capita was comparable with levels in the poorest countries in the world. In 2004, South Korea joined the trillion-dollar club of world economies.
Beginning in the 1960s under President PARK Chung-hee, the government promoted the import of raw materials and technology, encouraged saving and investment over consumption, kept wages low, and directed resources to export-oriented industries that remain important to the economy to this day. Growth surged under these policies, and frequently reached double-digits in the 1960s and 1970s. Growth gradually moderated in the 1990s as the economy matured, but remained strong enough to propel South Korea into the ranks of the advanced economies of the OECD by 1997. These policies also led to the emergence of family-owned chaebol conglomerates such as Daewoo, Hyundai, and Samsung, which retained their dominant positions even as the government loosened its grip on the economy amid the political changes of the 1980s and 1990s.
The Asian financial crisis of 1997-98 hit South Korea’s companies hard because of their excessive reliance on short-term borrowing, and GDP ultimately plunged by 7% in 1998. South Korea tackled difficult economic reforms following the crisis, including restructuring some chaebols, increasing labor market flexibility, and opening up to more foreign investment and imports. These steps lead to a relatively rapid economic recovery. South Korea also began expanding its network of free trade agreements to help bolster exports, and has since implemented 16 free trade agreements covering 58 countries—including the United State and China—that collectively cover more than three-quarters of global GDP.
In 2017, the election of President MOON Jae-in brought a surge in consumer confidence, in part, because of his successful efforts to increase wages and government spending. These factors combined with an uptick in export growth to drive real GDP growth to more than 3%, despite disruptions in South Korea’s trade with China over the deployment of a US missile defense system in South Korea.
In 2018 and beyond, South Korea will contend with gradually slowing economic growth - in the 2-3% range - not uncommon for advanced economies. This could be partially offset by efforts to address challenges arising from its rapidly aging population, inflexible labor market, continued dominance of the chaebols, and heavy reliance on exports rather than domestic consumption. Socioeconomic problems also persist, and include rising inequality, poverty among the elderly, high youth unemployment, long working hours, low worker productivity, and corruption.
|
Source : CIA |
Basic Information
|
Company Name |
HAN LIM PHARM CO., LTD. |
|
Registered Address |
2-27,
Yeongmun-ro, Cheoin-gu, Yongin-si, Gyeonggi-do, Korea (Old Address System : 1007, Yubang-dong, Cheoin-gu, Yongin-si, Gyeonggi-do, Korea) |
|
Zip Code |
17040 |
|
Tel |
+82-31-336-0540 |
|
Fax |
+82-31-336-0544 |
|
E-mail |
master@hanlim.com |
|
Website |
www.hanlim.com |
|
Trading Address |
42, Seocho-daero 52-gil, Seocho-gu, Seoul,
Korea (Old Address System : 1656-10,
Seocho-dong, Seocho-gu, Seoul, Korea) |
|
Tel |
+82-2-3489-6000 |
|
Fax |
+82-2-3489-6104 |
|
Other Address |
99, Asiad-daero, Yeonje-gu, Busan, Korea (Old Address System : 891-6, Geoje-dong,
Yeonje-gu, Busan, Korea) |
|
Type |
Export/Import |
|
Industry |
Manufacture of Finished Products,
Pharmaceuticals, Bulk Drugs |
|
Main
Business |
Antiinflammatory, Analgesics,
Antirheumatics, Antibacterials, Alimentary Drugs, Allergy & ENT Disease
Related Agents |
|
Sub
Business |
|
|
Established (mm/dd/yyyy) |
03/14/1989 |
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Antiinflammatory, |
|
Sell |
Antirheumatics |
|
Sell |
Antibacterials |
|
Sell |
Alimentary Drugs |
|
Sell |
Non narcotic analgesics and antipyretics(51142000) |
|
Sell |
Formulas and products for nutritional support(42231800) |
CEO’s
|
Name |
Kim Jung-Jin |
|
Date of Birth |
05/13/1967 |
|
Title |
President & CEO |
|
Nationality |
Korean |
Profiles
|
Capital (KRW) |
9,255,695,000 |
|||||||||
|
Employees |
342 |
|||||||||
|
Formation |
Co., Ltd by Shares |
|||||||||
|
Bank Details |
Woori Bank |
|||||||||
|
Corporate Registered No. |
134511-0007341 |
|||||||||
|
Business Registered No. |
135-81-02638 |
|||||||||
|
Permit & Licenses |
N/A |
|||||||||
|
Shareholder Position |
|
|||||||||
|
Company History |
03/14/1989 Incorporated as the present name 12/01/2008 Split off Sales Business, and
Established HANLIM MS CO., LTD. 12/15/2013 Increased the authorized shares
to 15,000,000 shares from 4,000,000 shares 02/27/2014 Decreased capital to
9,255,695,000 KRW from 9,316,820,000 KRW |
Detailed Information
Management
|
Job Description |
Name |
Nationality |
Date of Birth |
Inauguration Date |
|
Chairman & CEO |
Kim Jae-Yoon |
Korean |
04/20/1935 |
03/30/2017 |
|
President & CEO |
Kim Jung-Jin |
Korean |
05/13/1967 |
03/30/2017 |
|
Director |
Kim Ho-Jin |
Korean |
06/18/1964 |
03/30/2017 |
|
Auditor |
Won Mi-Ja |
Korean |
02/09/1943 |
11/08/2008 |
Financials
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
2016 |
148,628,887,531 |
239,565,425,557 |
30,233,956,983 |
|
2015 |
130,702,436,398 |
204,063,780,074 |
32,242,065,228 |
|
2014 |
130,347,190,569 |
170,697,891,540 |
32,681,063,043 |
|
2013 |
116,792,828,649 |
143,280,214,277 |
25,024,250,006 |
|
2012 |
99,567,746,862 |
113,384,142,036 |
9,989,972,978 |
Financial Description
|
Authorized Capital(KRW) |
75,000,000,000 |
|
Paid-Up Capital(KRW) |
9,255,695,000 |
|
Total Issued Shares |
1,851,139 |
|
Balance Sheet |
|||
|
Unit : Korean Won |
As of 12/31/2016 |
As of 12/31/2015 |
As of 12/31/2014 |
|
Total Assets |
239,565,425,557 |
204,063,780,074 |
170,697,891,540 |
|
Current Assets |
115,586,706,822 |
98,223,015,636 |
79,323,237,516 |
|
-Quick Assets |
89,901,298,574 |
77,026,695,807 |
58,411,932,908 |
|
-Inventories |
25,685,408,248 |
21,196,319,829 |
20,911,304,608 |
|
Fixed Assets |
123,978,718,735 |
105,840,764,438 |
91,374,654,024 |
|
-Investment |
33,816,765,132 |
29,484,771,456 |
25,282,877,787 |
|
-Tangibles |
87,634,763,614 |
73,774,786,226 |
65,383,155,817 |
|
-Intangibles |
115,000,000 |
175,000,000 |
235,000,000 |
|
-Others |
2,412,189,989 |
2,406,206,756 |
473,620,420 |
|
Total Liabilities |
68,465,577,078 |
57,181,686,828 |
48,375,636,672 |
|
Current Liabilities |
58,364,219,572 |
48,275,561,405 |
39,946,961,653 |
|
Fixed Liabilities |
10,101,357,506 |
8,906,125,423 |
8,428,675,019 |
|
Capital Stock |
9,255,695,000 |
9,255,695,000 |
9,255,695,000 |
|
Capital Surplus |
6,203,457,222 |
6,203,457,222 |
6,203,457,222 |
|
Profit Surplus |
147,231,739,001 |
123,013,983,768 |
98,454,145,390 |
|
Capital Adjustment |
8,408,957,256 |
8,408,957,256 |
8,408,957,256 |
|
Total Equity |
171,099,848,479 |
146,882,093,246 |
122,322,254,868 |
|
Liab. & Shareholder’s Equity |
239,565,425,557 |
204,063,780,074 |
170,697,891,540 |
|
Current
Liabilities |
58,364,219,572 |
48,275,561,405 |
39,946,961,653 |
|
Trade Payables |
11,670,679,074 |
7,267,308,824 |
4,037,895,519 |
|
Short-Term Borrowings |
36,700,000,000 |
29,350,000,000 |
18,800,000,000 |
|
Deferred Income Tax |
2,176,022,763 |
5,299,239,209 |
5,098,216,821 |
|
Account Payables |
2,214,986,205 |
1,721,080,678 |
5,184,358,141 |
|
Withholdings |
535,229,940 |
411,207,450 |
958,192,150 |
|
Advance Receipts |
48,550,656 |
524,159,398 |
706,470,127 |
|
Accrued Expenses |
881,579,931 |
606,213,417 |
550,546,882 |
|
VAT Withhold |
1,366,552,650 |
276,539,900 |
1,511,212,230 |
|
Guarantee Deposit Withhold |
2,185,000,000 |
2,235,000,000 |
2,515,000,000 |
|
Provision for Refund |
585,618,353 |
584,812,529 |
585,069,783 |
|
Fixed
Liabilities |
10,101,357,506 |
8,906,125,423 |
8,428,675,019 |
|
Provision for Severance & Retirement |
1,314,699,054 |
303,258,711 |
500,240,653 |
|
Long-Term Account Payables |
288,604,631 |
230,912,056 |
231,433,474 |
|
Deferred Income Tax Credit |
8,498,053,821 |
8,371,954,656 |
7,697,000,892 |
|
Income Statement |
|||
|
Unit : Korean Won |
As of 12/31/2016 |
As of 12/31/2015 |
As of 12/31/2014 |
|
Sales |
148,628,887,531 |
130,702,436,398 |
130,347,190,569 |
|
Cost of Sold Goods |
99,005,405,237 |
81,582,359,785 |
80,575,340,289 |
|
Gross Profit |
49,623,482,294 |
49,120,076,613 |
49,771,850,280 |
|
Selling & Admin. Expenses |
18,898,825,586 |
12,846,110,647 |
13,613,788,300 |
|
Operating Income |
30,724,656,708 |
36,273,965,966 |
36,158,061,980 |
|
Non-Operating Income |
8,256,388,734 |
7,873,293,522 |
6,887,939,574 |
|
Non-Operating Expenses |
2,718,549,219 |
1,642,395,890 |
2,235,441,738 |
|
Income Before Taxes |
36,262,496,223 |
42,504,863,598 |
40,810,559,816 |
|
Income Taxes Expenses |
6,028,539,240 |
10,262,798,370 |
8,129,496,773 |
|
Net Income |
30,233,956,983 |
32,242,065,228 |
32,681,063,043 |
|
Cash Flows |
|||
|
Unit : Korean Won |
As of 12/31/2016 |
As of 12/31/2015 |
As of 12/31/2014 |
|
Cash Flows from Operating |
28,969,022,658 |
26,472,340,707 |
32,667,994,141 |
|
-Net Income |
30,233,956,983 |
32,242,065,228 |
32,681,063,043 |
|
-Exp. without Cash Outflow |
15,431,491,375 |
8,085,088,007 |
7,856,324,863 |
|
-Revenue without Cash Inflows |
-4,251,025,696 |
-4,308,087,250 |
-3,748,949,124 |
|
-Changes in Asset/ & Liability |
-12,445,400,004 |
-9,546,725,278 |
-4,120,444,641 |
|
Cash Flows from Investing |
-24,744,183,645 |
-26,510,175,303 |
-28,784,688,770 |
|
-Cash Inflow from Investing |
55,405,523,571 |
44,416,464,232 |
25,952,381,229 |
|
-Cash Outflows for Investing |
-80,149,707,216 |
-70,926,639,535 |
-54,737,069,999 |
|
Cash Flows from Financing |
1,333,798,250 |
2,867,773,150 |
-7,905,695,000 |
|
-Cash Inflows from Financing |
121,772,192,924 |
145,488,686,740 |
148,457,980,051 |
|
-Cash Outflows from Financing |
-120,438,394,674 |
-142,620,913,590 |
-156,363,675,051 |
|
Increase/Decrease in Cash |
5,558,637,263 |
2,829,938,554 |
-4,022,389,629 |
|
Cash at the Beginning of Year |
4,810,638,560 |
1,980,700,006 |
6,003,089,635 |
|
Cash at the End of Year |
10,369,275,823 |
4,810,638,560 |
1,980,700,006 |
Products, Technologies, Services Description
|
Main Products & Services |
Antiinflammatory, Analgesics,
Antirheumatics, Antibacterials, Alimentary Drugs, Allergy & ENT Disease
Related Agents |
|
Detailed Products Spec. |
|
|
Technologies Acquired |
|
Trade Partners & Competitors
|
Competitors |
DONGA PHARMACEUTICAL
CO.,LTD.(110111-0017990) YUHAN CORPORATION(110111-0014409) CHONGKUNDANG CO.,LTD.(110111-0028955) DAEWOONG PHARMA CO.,LTD.(134811-0075342) |
Related Parties (Subsidiaries, Joint-Venture & Affiliates)
|
Affiliates |
HANLIM MS CO., LTD.(134511-0132891) |
|
Subsidiary |
HLGENOMICS CO., LTD.(134511-0044624) (100.0% held by the subject company) |
|
Cooperative Enterprise |
-Insured Company SAMSUNG FIRE & MARINE INSURANCE CO., LTD.(110111-0005078) HANWHA GENERAL INSURANCE CO., LTD.(110111-0006456) |
Sales by Region (Activity & Markets)
Not Available.
Court Action
No Records.
News Clipping
--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 64.03 |
|
|
1 |
INR 90.40 |
|
Euro |
1 |
INR 79.73 |
|
KRW |
1 |
INR 0.059 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
PRA |
|
|
|
|
Report Prepared
by : |
SYL |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.